A study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP inhibitors.

A new study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP ...

Single-molecule imaging revealed that BRCA2 functions as a molecular shield, physically preventing PARP1 from remaining stuck at DNA repair sites, the mechanism by which PARP inhibitors have their ...

Inherited mutations in the gene BRCA2 significantly increase the risk of carriers to breast and ovarian cancers.  BRCA2, a crucial player in the body& | Cancer ...

PARP inhibitors, used in BRCA2-deficient cancer treatment, trap PARP1, destabilizing repair complexes. BRCA2 protects these complexes, but the effectiveness of PARP inhibitors diminishes over time.

The trial focused on stenoparib, a novel dual PARP/Wnt pathway inhibitor, and its effectiveness ... aimed at further understanding stenoparib’s mechanism and advancing it toward regulatory ...

Cash and cash receivable balance of $20.9 million as of December 31, 2024, expected to fund operations, including clinical activities ...

Cash and cash receivable balance of $20.9 million as of December 31, 2024, expected to fund operations, including clinical activities into 2027Strengthened cash position expected to support ...